- Title
- BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
- Creators - without role
- Hervé Ghesquières - Centre Léon BérardCécile Dalban - Centre Léon BérardEmmanuelle Nicolas‐virelizier - Centre Léon BérardFabrice Jardin - Université de Rouen NormandieFabien Le Bras - Centre Hospitalier Universitaire Henri-MondorSteven Le Gouill - Centre Hospitalier Universitaire de NantesRené-Olivier Casasnovas - Centre de recherche Translationnelle en Médecine moléculaireSéraphine Vizoso - Centre Léon BérardCaroline Hernandez - Centre Léon BérardSéverine Metzger - Centre Léon BérardDavid Pérol - Centre Léon BérardGuillaume Cartron - Université de Montpellier, Institut de Génétique Moléculaire de Montpellier - IGMM
- Publication Details
- British Journal of Haematology, Vol.192(3), pp.e94-e98
- Grant note
- Centre Léon Bérard, sponsor of the study, was responsible for trial conception, coordination, data analysis, and writing of the report. This work was supported by the French Health ministry (PHRC-K 2012), and Mundipharma provided the study drug bendamustine and funding to Centre Léon Bérard to conduct the study.
- Identifiers
- 9936653709311
- Academic Unit
- Institut de Génétique Moléculaire de Montpellier - IGMM
- Language
- English
- Resource Type
- Journal article
- Local Fields
- inserm-03349131
Journal article
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
British Journal of Haematology, Vol.192(3), pp.e94-e98
02/2021
PMID: 33421031
Metrics
1 Record Views